Quality control guidelines for BAL9141 (Ro 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used

Journal of Clinical Microbiology

Volumn 42, Issue 7, 2004, Pages 3356-3358

  Anderegg, T R ^a   Jones, R N ^a,b   Sader, H S ^a  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOBIPROLE; CEPHALOSPORIN DERIVATIVE; RO 639141; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; DISK DIFFUSION SUSCEPTIBILITY TEST; DRUG APPROVAL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL;

CEPHALOSPORINS; DIFFUSION; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 3142669001     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.7.3356-3358.2004     Document Type: Article

References (12)

1. Eliopoulos, G. M. 2003. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin. Infect. Dis. 36:473-481.
2. Entenza, J. M., P. Hohl, I. Heinze-Krauss, M. P. Glauser, and P. Moreillon. 2002. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46:171-177.
3. Gavan, T. L., R. N. Jones, A. L. Barry, P. C. Fuchs, E. H. Gerlach, J. M. Matsen, L. B. Reller, C. Thornsberry, and L. D. Thrupp. 1981. Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study. J. Clin. Microbiol. 14:67-72.
4. Goldstein, F. W., and M. D. Kitzis. 2003. Vancomycin-resistant Staphylococcus aureus: no apocalypse now. Clin. Microbiol. Infect. 9:761-765.
5. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. P. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococci. Antimicrob. Agents Chemother. 45:825-836.
6. Jones, R. N. 2003. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY antimicrobial surveillance program (1997-2001). Semin. Respir. Crit. Care Med. 24:121-133.
7. Jones, R. N., L. M. Deshpande, A. H. Mutnick, and D. J. Biedenbach. 2002. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50:915-932.
8. Liu, C., and H. F. Chambers. 2003. Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. Antimicrob. Agents Chemother. 47:3040-3045.
9. National Committee for Clinical Laboratory Standards. 2001. Development of in vitro susceptibility testing criteria and quality control parameters, 2nd ed. Document M23-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa.
10. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial disk susceptibility tests; approved standard, 8th ed. Document M2-AS. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 6th ed. Document M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
12. National Committee for Clinical Laboratory Standards. 2004. Performance standards for antimicrobial susceptibility testing, 14th information supplement. Document M100-S14. National Committee for Clinical Laboratory Standards, Wayne, Pa.